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Abstract
Aims Chronic kidney disease (CKD) in heart failure (HF) increases the risk of hyperkalaemia (HK), limiting angiotensin-
converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) use. Patiromer is a sodium-free, non-absorbed
potassium binder approved for HK treatment. We retrospectively evaluated patiromer’s long-term safety and efficacy in HF
patients from AMETHYST-DN.
Methods and results Patients with Type 2 diabetes, CKD, and HK [baseline serum potassium >5.0–5.5 mmol/L (mild) or
>5.5–<6.0 mmol/L (moderate)], with or without HF (New York Heart Association Class I and II, by investigator judgement),
on ACE-I/ARB, were randomized to patiromer 8.4–33.6 g to start, divided twice daily. Overall, 105/304 (35%) patients had
HF (75%, Class II). Mean (standard deviation) ejection fraction (EF) was 44.9% (8.2) (n = 81) in patients with HF; 26 had EF
≤40%. In HF patients, mean serum potassium decreased by Day 3 through Week 52. At Week 4, estimated mean (95% confi-
dence interval) change in serum potassium was 0.64 mmol/L (0.72, 0.55) in mild and 0.97 mmol/L (1.14, 0.80) in
moderate HK (both P < 0.0001). Most HF patients with mild (>88%) and moderate (≥73%) HK had normokalaemia at each
visit from Weeks 12 to 52. Three HF patients were withdrawn because of high (n = 1) or low (n = 2) serum potassium. The
most common patiromer-related adverse event was hypomagnesaemia (8.6%).
Conclusions In patients with a clinical diagnosis of HF, diabetes, CKD, and HK on ACE-I/ARB, patiromer was well tolerated
and effective for HK treatment over 52 weeks.
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Introduction
Renin–angiotensin–aldosterone system inhibitors (RAASi),
such as an angiotensin-converting enzyme inhibitor (ACE-I)
or an angiotensin receptor blocker (ARB) and a
mineralocorticoid receptor antagonist (MRA), are indicated
in patients with heart failure (HF) to reduce cardiovascular
morbidity and mortality.1–5 However, these patients often
have co-morbid conditions such as chronic kidney disease
(CKD) and/or Type 2 diabetes mellitus (DM) that increase
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their risk of developing hyperkalaemia.6–9 The use of RAASi
further amplifies the risk of developing hyperkalaemia in
these patients, especially those with CKD or who receive ≥1
RAASi.10–13 The fear of inducing hyperkalaemia has led to
underuse of RAASi in these patients.14
Patiromer is a sodium-free, non-absorbed potassium
binder that reduces serum potassium by exchanging calcium
for potassium throughout the gut lumen but predominantly
in the colon, where potassium concentration is high.14,15
The use of calcium rather than sodium as the counter-
exchange ion in patiromer prevents the risk of adding a
sodium load to patients who are already at greater risk for
fluid overload because of their underlying heart or kidney dis-
ease.14,15 Patiromer has been approved for the treatment of
hyperkalaemia in the USA16 and in the European Union.17
Patiromer has been demonstrated to be well tolerated and
effective over the short term in reducing serum potassium
in patients with hyperkalaemia (serum potassium >5.0 to
<6.5 mmol/L) or preventing hyperkalaemia in patients with
CKD and HF.18–20 In one of these short-term studies, a signif-
icantly higher proportion of patients with HF on patiromer
were able to have their spironolactone dose increased vs.
those on placebo.20
More recently, the reduction in serum potassium that has
been observed after 4 weeks of patiromer treatment has
been shown to be maintained for up to 52 weeks in the
AMETHYST-DN study in hyperkalaemic patients with DM
and CKD on RAASi therapy.21 Mean serum potassium levels
increased in patients discontinuing patiromer, either prema-
turely or at Week 52, suggesting that chronic therapy may
be needed to control serum potassium in these patients.21
However, the long-term safety and effectiveness of patiromer
in patients with HF has not previously been examined. We
therefore conducted a retrospective subanalysis of the
AMETHYST-DN study21 in patients with or without a clinical
diagnosis of HF at baseline.
Methods
Study populations
The AMETHYST-DN study has been described previously.21
Briefly, eligible patients were 30 to 80 years of age, had DM
and CKD (estimated glomerular filtration rate 15 to
<60 mL/min/1.73 m2), and were hyperkalaemic (mild: >5.0
to 5.5 mmol/L; moderate: >5.5 to <6.0 mmol/L; at screening
or after an up-to-4-week run-in period). Patients with or
without a clinical diagnosis of HF on a stable dose of RAASi
for ≥28 days at screening were enrolled. The presence of
HF was determined by the investigator using the patients’ re-
ported history and medical records (when available). The
date of HF diagnosis and left ventricular ejection fraction
(EF) (when available) and current New York Heart Association
(NYHA) class were recorded in the case report form. No spe-
cific diagnostic criteria were provided to investigators by the
sponsor.
Key exclusion criteria included current diagnosis of NYHA
Class III or IV HF; occurrence of unstable angina (as assessed
by the investigator), unresolved acute coronary syndrome,
cardiac arrest, clinically significant ventricular arrhythmia,
transient ischaemic attack, or stroke during the 2 months
prior to screening; type 1 diabetes; prior kidney transplant;
haemoglobin A1c >12% at screening (except for patients
with hyperkalaemia at screening); urine albumin-to-
creatinine ratio ≥1130 mg/mmol (except for patients with
hyperkalaemia at screening); and serum magnesium
<0.58 mmol/L at screening.21
Study design
AMETHYST-DN was a multicentre, randomized, open-label
Phase 2B study performed at 48 sites in five European
countries.20 The protocol was approved by local or national
independent ethics committees at each study site and per-
formed in accordance with the International Conference on
Harmonisation E6 Guideline for Good Clinical Practice, the
Declaration of Helsinki principles, and the European Union
Clinical Trials Directive 2001/20/EC for sites in the European
Union.22–24 All patients provided written informed consent
before any study-specific procedures were performed.
The 52-week study included an 8-week treatment period
and a 44-week long-term maintenance period (LTMP)
(Figure 1). The treatment period was preceded by an up-
to-4-week run-in period, and LTMP was followed by an up-
to-4-week follow-up period. At screening, patients on RAASi
who were normokalaemic (serum potassium of 4.3–
5.0 mmol/L) and had uncontrolled hypertension [sitting
systolic blood pressure (BP) of >130 to ≤180 mmHg and dia-
stolic BP of >80 to ≤110 mmHg] entered the run-in period.21
The patients were randomly assigned in a 3:1 ratio to either
switch from their current ACE-I or ARBmedications to losartan
100 mg/day (Cohort 1) or receive spironolactone 25 mg/day in
addition to their current ACE-I or ARB medications (Cohort 2).
Additionally, patients in Cohorts 1 and 2 could receive up to
50 mg/day spironolactone if necessary for managing
hypertension. Cohort 3 patients [with pre-existing
hyperkalaemia (baseline serum potassium >5.0 to
<6.0 mmol/L)] did not enter the run-in period and continued
to take their ACE-I or ARB medications.
Patients who developed hyperkalaemia (serum potassium
>5.0 to <6.0 mmol/L) during the run-in period (Cohorts 1
and 2) and patients with pre-existing hyperkalaemia at
screening (Cohort 3) entered the treatment period and were
assigned to one of two strata: mild hyperkalaemia (serum po-
tassium >5.0 to 5.5 mmol/L) and moderate hyperkalaemia
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(>5.5 to <6.0 mmol/L). The patients were randomized to re-
ceive one of three starting doses of patiromer in each stra-
tum: mild hyperkalaemia patients received 4.2, 8.4, or
12.6 g twice daily; and moderate hyperkalaemia patients re-
ceived 8.4, 12.6, or 16.8 g twice daily. Following the baseline
visit (Day 1), patients were assessed at Day 3 (approximately
48 h after the first patiromer dose) and weekly thereafter
during the 8-week treatment period and monthly during
the 44-week LTMP. The starting dose could be titrated up
or down in a stepwise manner, starting at Day 3 and up to
the Week 52 visit to achieve and maintain serum potassium
≤5.0 mmol/L (4.0–5.0 mmol/L during the treatment period
and 3.8–5.0 mmol/L during the LTMP). By protocol, RAASi
could not be down-titrated or discontinued secondary to
hyperkalaemia, although patiromer could be up-titrated
using the study-defined dosing algorithm. Irrespective of
whether they completed the entire 52-week study period,
all patients continued into the follow-up period. As reported
previously, patiromer decreased the mean serum potassium
significantly from baseline to Week 4 in all starting-dose
groups in both strata (P< 0.001 for each comparison); the re-
ductions were maintained through Week 52.21 In the present
analyses, the data for the three starting-dose groups with
each baseline hyperkalaemia strata were combined for the
purpose of comparing the patiromer effect on serum potas-
sium in patients with and without a clinical diagnosis of HF.
Patients with serum potassium >5.0 mmol/L at the end-of-
treatment visit discontinued patiromer and all RAASi medica-
tions and returned for two follow-up visits within 7 days. Pa-
tients who were normokalaemic (serum potassium
≤5.0 mmol/L) at the end-of-treatment visit discontinued
patiromer but remained on RAASi for 28 days and returned
for five follow-up visits (Day 3 and weekly visits through Week
4 post-treatment) during this period. Patients who developed
significant hyperkalaemia during the follow-up period were
treated as per standard of care (as determined by the investiga-
tor). This follow-up design helped assess the effect of patiromer
withdrawal on serum potassium in patients receiving RAASi.
Efficacy and safety assessments
In the HF subgroup, the same efficacy endpoints as in the
AMETHYST-DN study were used.21 We studied change in se-
rum potassium from baseline to Week 4 (or prior to the first
dose titration if it occurred before 4 weeks) and change in se-
rum potassium from baseline to other post-baseline visits. All
serum potassium assessments (including baseline values)
were based on central laboratory serum potassium.
Long-term safety and tolerability were assessed over
52 weeks by frequency and severity of adverse events
(AEs), clinical laboratory measurements, vital signs, and
electrocardiogram parameters. Safety measures also included
the proportion of patients who met the withdrawal criterion
of serum potassium <3.5 mmol/L. Results are presented for
the combined baseline hyperkalaemia strata in each sub-
group (HF vs. no HF), except for serum potassium over time.
Statistical analyses
The detailed statistical analyses for the AMETHYST-DN study
have been described previously.21 For this analysis, serum
Figure 1 AMETHYST-DN study design. *eGFR 15 to <60 mL/min/1.73 m2. †Primary endpoint. ‡RAASi therapy was continued after patiromer discon-
tinuation only in patients who were normokalaemic (serum K+ ≤ 5.0 mEq/L) at the last on-treatment visit. ACR, albumin-to-creatinine ratio; BID, twice
daily; BP, blood pressure; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; K+, potassium; PRN, as
needed; RAASi, renin–angiotensin–aldosterone system inhibitors; spiro, spironolactone; Wk, week.
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potassium levels at post-baseline time points through Week 52
were estimated for each stratum using a mixed-effects
repeated-measures model with central laboratory serum potas-
sium value as the dependent variable, time point and starting
dose as fixed-effect predictors, baseline central laboratory se-
rum potassium value as a continuous covariate, and patient as
a random effect. A compound symmetry correlation matrix




Of the 306 patients who were randomized in the AMETHYST-
DN study, 105 were assessed by the investigators as having a
clinical diagnosis of NYHA Class I or II HF. In total, 78 (74.3%)
patients with HF and 133 (66.2%) without HF completed the
entire study. The most common reasons for discontinuation
in patients with and without HF were consent withdrawal [7
(6.7%) and 24 (11.9%), respectively] and AEs [7 (6.7%) and 12
(6.0%), respectively] (Supporting Information, Table S1). Dis-
continuations due to low serum potassium occurred in two
(1.9%) patients with HF and five (2.5%) patients without HF.
Discontinuations due to high serum potassium occurred in
one (1.0%) patient with HF and six (3.0%) patients without HF.
Demographic and baseline characteristics
All 105 patients with HF and 199 of 201 patients without HF
were treated with at least one dose of patiromer and are
included in the safety and efficacy analyses. All patients were
White, and the majority (68.6% with HF) were men (Table 1).
Table 1 Demographic and clinical characteristics at baseline or screening
Parameter Patients with HF (n = 105) Patients without HF (n = 199)
Age at screening (years), mean ± SD 67.7 ± 7.3 65.6 ± 9.1
Male, n (%) 72 (68.6) 120 (60.3)
White, n (%) 105 (100) 199 (100)
Body mass index (kg/m2), mean ± SD 29.0 (3.2) 30.0 (4.6)
Serum potassium (mmol/L), mean ± SD (n) 5.08 ± 0.42 (103) 5.12 ± 0.46 (198)
5.0 to <5.5, n (%) 77 (73.3) 143 (71.9)
5.5 to <6.0, n (%) 28 (26.7) 56 (28.1)
eGFR at screening (mL/min/1.73 m2), mean ± SD (n) 40.0 ± 14.89 (102) 40.9 ± 16.1 (196)
CKD stage (eGFR, mL/min/1.73 m2) at screening, n (%)
1 (≥90) 0 1 (0.5)
2 (60–89) 8 (7.6) 21 (10.6)
3a (45–59) 32 (30.5) 53 (26.6)
3b (30–44) 37 (25.2) 74 (37.2)
4 (15–29) 21 (20.0) 45 (22.6)
5 (<15) 4 (3.8) 2 (1.0)
NYHA class at screening, n (%)
I 26 (24.8) 0
II 79 (75.2) 0
No 0 199 (100)
Hypertension, n (%) 105 (100) 199 (100)
Sitting BP at screening (mmHg), mean ± SD
Systolic 155.4 ± 12.4 155.6 ± 11.8
Diastolic 86.4 ± 11.3 82.7 ± 11.2
Ejection fraction (%), mean ± SD (n) 44.9 ± 8.2 (81) 54.7 ± 6.6 (84)
Urine ACR (mg/mmol), mean ± SD (n) 118.0 ± 200.9 (100) 136.1 ± 211.1 (193)
RAASi medication, n (%)
ACE-I 71 (67.6) 128 (64.3)
ARB 47 (44.8) 95 (47.7)
Aldosterone antagonist 5 (4.8) 20 (10.1)
On any single RAASi 88 (87.3) 160 (80.4)
On ≥2 RAASia 17 (16.3) 39 (19.5)
On losartan 100 mg ± any dose of spironolactoneb 15 (14.3) 43 (21.6)
Digitalis/digoxin, n (%) 22 (21.0) 1 (0.5)
Beta-blocker, n (%) 62 (59.0) 101 (50.8)
Non-RAASi diuretic, n (%)c 67 (63.8) 63 (31.7)
ACE-I, angiotensin-converting enzyme inhibitor; ACR, albumin-to-creatinine ratio; ARB, angiotensin receptor blocker; BP, blood pressure;
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HF, heart failure; NYHA, New York Heart Association; RAASi, re-
nin–angiotensin–aldosterone system inhibitor; SD, standard deviation.
aOf these patients, one patient with HF and five patients without HF were on triple-RAASi therapy (i.e. ACE-I, ARB, and mineralocorticoid
receptor antagonist).
bThis category includes only patients in Cohort 1 (n = 58), of whom 24 (five with HF) were on at least 25 mg of spironolactone daily.
cIncludes loop and thiazide diuretics.
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In the HF subgroup, the mean [standard deviation (SD)] age
was 67.7 (7.53) years (range: 49–80 years), and the mean
(SD) serum potassium was 5.08 (0.42) mmol/L. Seventy-seven
(73.3%) HF patients had serum potassium >5.0 to 5.5 mmol/
L (mild hyperkalaemia) at baseline, and 28 (26.7%) had serum
potassium >5.5 to 6.0 mmol/L (moderate hyperkalaemia) at
baseline. Of the patients with HF, 79 (75%) had NYHA Class
II. Eighty-one patients with HF had EF recorded at baseline
(Table 2); mean (SD) EF was 44.9% (8.2%) in these patients.
Of the 105 patients with HF, 16 (15.2%) had electrocardio-
graphic evidence of atrial fibrillation at baseline. All patients
with HF were on RAASi medications, mostly monotherapy
with an ACE-I or an ARB (Table 1).
Efficacy
Mean serum potassium was reduced at the first post-baseline
visit (Day 3, when patients remained on their starting dose)
through Week 52 in patients with and without HF, regardless
of baseline hyperkalaemia severity (Figure 2). At Week 4 (or
at the time of first titration if it occurred before Week 4), the
least squares mean (LSM) (95% confidence interval [CI]) change
in serum potassium from baseline in HF patients was 0.64
(0.72, 0.55) mmol/L for those with mild hyperkalaemia
and 0.97 (1.14, 0.80) mmol/L for those with moderate
hyperkalaemia (P < 0.0001 for both). Results in patients with-
out HF were 0.60 (0.67, 0.53) mmol/L for mild
hyperkalaemia and 1.01 (1.15, 0.88) mmol/L for moder-
ate hyperkalaemia (P< 0.0001 for both). FromWeek 4 through
Week 52, significant (P < 0.0001) mean decreases from base-
line in mean serum potassium levels were observed at each
monthly time point in patients with or without HF, irrespective
of hyperkalaemia stratum (Figure 2). In the HF subgroup over-
all, ≥88% of patients with mild hyperkalaemia and ≥73% with
moderate hyperkalaemia had serum potassium levels within
the target range of 3.8 to 5.0 mmol/L at each scheduled visit
during the LTMP (Weeks 12 to 52). In the subgroup without
HF, the proportions were ≥84% and ≥79%, respectively.
Efficacy results in the 26 patients with EF ≤40% (both
strata combined) were consistent with the overall HF sub-
group, with an LSM change in serum potassium of
0.37 mmol/L (95% CI: 0.74, 0.00) at Day 3 and
0.66 mmol/L (95% CI: 1.12, 0.20) at Week 4. Between
Weeks 1 and 52, mean serum potassium remained between
4.5 and <5.0 mmol/L in all 26 with EF ≤40%.
Discontinuation of patiromer led to a significant rise in se-
rum potassium in patients with or without HF (Figure 2).
Three days after patiromer was discontinued, the LSM (95%
CI) increase in serum potassium from the Week 52 time point
in HF patients was 0.27 (0.18, 0.36) mmol/L for those with
mild hyperkalaemia (P < 0.0001) and 0.46 (0.20, 0.71)
mmol/L for those with moderate hyperkalaemia
(P = 0.0011). The corresponding LSM increase in serum
potassium in patients without HF was 0.24 (95% CI: 0.15,
0.32) mmol/L for those with mild hyperkalaemia
(P < 0.0001) and 0.27 (95% CI: 0.14, 0.40) mmol/L for those
with moderate hyperkalaemia (P = 0.0001). Similar increases
in serum potassium after patiromer discontinuation were
observed in the subgroup with EF ≤40%.
The majority of patients with HF had either no titrations or
one titration during the first 8 weeks of the study, with a dose
increase being more common than a dose decrease. During
the first 4 weeks, 65 (61.9%) HF patients had no dose adjust-
ments, while 30 (28.6%) had one dose adjustment. During
Weeks 4 to 8, the proportions with no titration or one titra-
tion were 62.6% and 24.2%, respectively (Table S2).
Safety
Patiromer was generally well tolerated (Table 3). Among the
patients with HF, 74 (71%) reported at least one AE during
the study; 13% reported AEs that were considered by the












Yes, NYHA Class I, n (%) 1 (3.8) 3 (7.5) 8 (53.3)
Yes, NYHA Class II, n (%) 25 (96.2) 37 (92.5) 7 (46.7)
No 0 0 0
Ejection fraction (%)
N 26 40 15
Mean (SD) 37.4 (2.7) 44.8 (2.6) 58.1 (7. 8)
Median 38.0 45.0 56.0
Quartiles (25th, 75th) 36.0, 39.0 42.0, 47.0 51.0, 60.0
EF, ejection fraction; HF, heart failure; NYHA, New York Heart Association; pEF, preserved ejection fraction; rEF, reduced ejection fraction;
SD, standard deviation.
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investigators to be related to patiromer. Hypomagnesaemia
(9.5%) and worsening of CKD (6.6%) were the two most com-
mon AEs (as AEs are defined by the investigator, these events
are not based on pre-specified laboratory criteria; see below
for details on laboratory-defined hypomagnesaemia,
hypokalaemia, and changes in renal function). AEs of
hypomagnesaemia did not lead to any discontinuations,
while worsening of CKD did in three (2.9%) patients (with on-
set during Week 3 in one patient, Week 4 in the second pa-
tient, and Week 41 in the third patient). Diarrhoea (none
severe) occurred in five (4.8%) and constipation (none se-
vere) occurred in four (3.8%) HF patients. The three most
common treatment-related AEs in HF patients were
hypomagnesaemia (8.6%), abdominal discomfort (1.9%),
and constipation (1.9%). Non-dose-dependent peripheral oe-
dema was reported in eight patients overall (8/304, 2.6%,
one patient with HF and seven patients without HF); none
were related to patiromer based on investigator assessment.
In no patient was peripheral oedema associated with events
of cardiac failure or worsening of CKD. Two (1.9%) patients
with HF had AEs of atrial fibrillation (new onset).
Of the 26 patients with EF ≤40%, 65% reported at least one
AE during the study. The most common AE in these 26 pa-
tients was ventricular extrasystoles, occurring in three pa-
tients; two patients each had AEs of hypoglycaemia,
hypomagnesaemia, thrombocytopaenia, and worsening of
CKD. Mild or moderate gastrointestinal AEs were the most
common class (occurring in two patients) of treatment-
Figure 2 Least squares mean (95% CI) serum potassium levels over 52 weeks and during the follow-up period in patients with (A) or without (B) HF.
Serum potassium values [mmol/L (95% CI)] at baseline were as follows: in the HF subgroup, 5.11 (5.03, 5.20) for mild and 5.61 (5.28, 5.94) for mod-
erate hyperkalaemia; and in the non-HF subgroup, 5.16 (5.08, 5.23) for mild and 5.74 (5.59, 5.89) for moderate hyperkalaemia. All serum potassium
analyses are based on central laboratory values. P-values for least squares mean changes from baseline (for 52 weeks of treatment period) and from
Week 52 (or time of last dose of patiromer; for follow-up period). Least squares mean values are based on a mixed-effects repeated-measures model
with serum potassium value as the dependent variable, time point and starting dose as fixed-effect predictors, baseline central laboratory serum po-
tassium value as a continuous covariate, and patient as a random effect. A compound symmetry matrix was fit. Least squares mean values for the
follow-up period are based on the same model described, while the baseline covariate used was the last potassium value before study termination.
The blue shaded area denotes the target range for serum potassium (4.0–5.0 mmol/L during the treatment period and 3.8–5.0 mmol/L during the
long-term maintenance period). CI, confidence interval; HF, heart failure; HK, hyperkalaemia; K+, potassium; LS, least squares; N, number of patients
at baseline and each successive 4-week interval. *P ≤ 0.001; †P < 0.01.
Patiromer for heart failure patients 597
ESC Heart Failure 2018; 5: 592–602
DOI: 10.1002/ehf2.12292
related AEs, with abdominal discomfort, nausea, and
vomiting each occurring in one patient with EF ≤40%.
Eight (7.6%) patients with HF (of whom five had EF ≤40%)
discontinued patiromer because of AEs. In seven of eight pa-
tients, the AE leading to discontinuation was not related to
patiromer in the judgement of the investigator. The most
common AE leading to discontinuation in patients with HF
was worsening of CKD [three (2.8%)]. Discontinuations due
to gastrointestinal AEs were infrequent, occurring in one pa-
tient with HF (abdominal discomfort).
Serious AEs (SAEs) were observed in 18 (17.1%) HF pa-
tients (four with EF ≤40%) and in 26 (13.1%) patients without
HF; none of these were attributed to patiromer, according to
investigators. The SAEs occurring in at least one patient with
HF are shown in Table S3. The most common SAEs in patients
with HF were sudden cardiac death [four (3.8%) patients] and
worsening of CKD [three (2.9%) patients]. In addition, events
of cardiac failure, regardless of seriousness, were summa-
rized as they are of special interest in an HF population. These
included AEs of cardiac failure or chronic HF (or worsening of
chronic HF), left ventricular failure, or acute left ventricular
failure and occurred in three (2.9%) patients with HF (two
with EF ≤40%) and in nine (4.5%) patients without HF. In
one of the three patients with HF (a patient with EF ≤40%)
and five of the nine patients without HF, the events were
serious (i.e. required hospitalization). No events of cardiac
failure were considered by the investigators to be related to
patiromer treatment. There were no reported events of
sustained ventricular arrhythmias. The safety profile in
patients without HF was generally consistent with that ob-
served in HF patients (Tables 3 and S3).
Over 52 weeks through follow-up, nine patients with HF
(three with EF ≤40%) and six without HF died. For seven of
nine patients with HF and five of six without HF, the cause
—as adjudicated by an independent safety review board
(SRB)—was cardiovascular (sudden cardiac death: four with
HF and three without HF; acute myocardial infarction: two
with HF and two without HF; stroke: one with HF). None of
the deaths were considered by the SRB to be related to
hyperkalaemia or hypokalaemia; none were considered by
the investigators to be related to patiromer.
Mean serum calcium, magnesium, and phosphate levels
remained within the normal ranges during the study (Table
S4). Mean serum calcium levels decreased slightly during
the first 4 weeks of patiromer treatment (by 0.2 mmol/L) in
patients with HF and remained either slightly decreased (in
those with mild hyperkalaemia at baseline) or increased
slightly by 0.2 mmol/L (in those with moderate
Table 3 Safety summary over 52 weeks
Parameter, n (%) Patients with HF (n = 105) Patients without HF (n = 199)
At least one AE 74 (70.5) 137 (68.8)
Most common AEs (≥5% of patients in any subgroup with or without HF)
Hypomagnesaemia 10 (9.5) 16 (8.0)
Worsening of CKD 7 (6.7) 21 (20.0)
Ventricular extrasystoles 7 (6.7) 4 (2.0)
Influenza 6 (5.7) 3 (1.5)
Hypoglycaemia 6 (5.7) 4 (2.0)
Diarrhoea 5 (4.8) 12 (6.0)
Worsening of HTN 4 (3.8) 20 (10.1)
Constipation 4 (3.8) 15 (7.5)
Most common patiromer-related AEs (≥5% of patients in any subgroup with or without HF)
Hypomagnesaemia 9 (8.6) 13 (6.5)
Constipation 2 (1.9) 12 (6.0)
Discontinuations due to any AE 8 (7.6) 20 (10.1)
Discontinuations due to gastrointestinal AEs 1 (1.0) 4 (2.0)
Abdominal discomfort 1 (1.0) 0 (0.0)
Constipation 0 (0.0) 2 (1.0)
Diarrhoea 0 (0.0) 1 (0.5)
Vomiting 0 (0.0) 1 (0.5)
Electrolytes of interest
Hypomagnesaemiaa
<0.58 mmol/L 15 (14.3) 31 (15.6)
<0.49 mmol/L 2 (1.9) 10 (5.0)
Hypokalaemiaa
<3.5 mmol/L 4 (3.8) 13 (6.5)
Other AEs of interest
Worsening of HF 3 (2.9) 1 (0.5)
Atrial fibrillation 2 (1.9) 5 (2.5)
Oedema 1 (1.0) 7 (3.5)
At least one serious AE 18 (17.1) 26 (13.1)
Deaths 9 (8.6) 6 (3.0)
AE, adverse event; CKD, chronic kidney disease; HF, heart failure; HTN, hypertension. In each subsection, AEs are presented in descending
incidence in the total HF group.
aBased on predefined laboratory criteria.
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hyperkalaemia at baseline) at Week 52. In patients with HF,
the mean [standard error (SE)] change in serum magnesium
from baseline to Week 52 was 0.05 (0.02) mmol/L in pa-
tients with mild hyperkalaemia and 0.04 (0.03) mmol/L in
those with moderate hyperkalaemia; the mean reductions
in serum magnesium in patients without HF were similarly
small (Table S4). In patients with EF ≤40% (n = 26), the mean
(SE) change in serum magnesium from baseline to Week 52
was 0.05 (0.03) mmol/L. By central laboratory measures,
serum magnesium <0.58 mmol/L was observed in 15
(14.3%) with HF (one with EF ≤40%) and in 31 (15.6%)
patients without HF during the entire 52-week treatment
period (Table 3). Serum magnesium levels <0.49 mmol/L
were seen in two (1.9%) HF (none with EF ≤40%) and 10
(5.0%) non-HF patients, and none had serum magnesium
<0.41 mmol/L. No patients with serum magnesium levels
of <0.58 or <0.49 mmol/L had cardiac arrhythmias
temporally associated with hypomagnesaemia or neuromus-
cular abnormalities other than myalgias. Hypokalaemia (pre-
defined as serum potassium <3.5 mmol/L by central labora-
tory measures) was seen in four (3.8%) patients with HF
(none with EF ≤40%) and 13 (6.5%) patients without HF
(Table 3). There were no clinically meaningful alterations in
the mean estimated glomerular filtration rate and mean
urine albumin-to-creatinine ratio during the study (Table S5).
In patients with HF, the mean systolic/diastolic BP at base-
line was 154/87 mmHg in patients with mild hyperkalaemia
and 155/83 mmHg in those with moderate hyperkalaemia.
A mean reduction from baseline to Week 52 in the
systolic/diastolic BP of 18/12 and 25/8 mmHg, respectively,
was observed (Table S6). One HF patient reported an AE of
mild dizziness. The mean baseline systolic/diastolic BP and
change over 52 weeks in patients without HF were generally
similar (Table S6). In the small group of patients with EF
≤40%, mean BP was 151/91 mmHg at baseline; 17/26
patients had baseline systolic BP ≥140 mmHg. Mean BP de-
creased from baseline to Week 52 by 17/16 in the patients
with EF ≤40%, with no reported AEs of hypotension or dizzi-
ness and no recorded systolic BP <107 mmHg.
Discussion
The results of this study confirm that patiromer is effective in
normalizing serum potassium in hyperkalaemic patients with
a clinical diagnosis of HF and coexisting CKD and diabetes,
with reductions in serum potassium at Week 4 (the primary
endpoint in the study21) consistent with those observed in
patients without HF based on overlapping CIs. The results
also show that serum potassium can be maintained within
the normal range in these patients for a period of up to 1 year
despite maintenance of ACE-I and ARB medications. The HF
patients enrolled in AMETHYST-DN had predominantly mild
symptoms and EF >40%. However, long-term efficacy results
were consistent in the small group of HF patients with EF
≤40%. The efficacy profile of patiromer was achieved with
no or only one titration in the majority of patients, which is
consistent with the titration data in the Phase 3 study
(OPAL-HK).25 This titration frequency may be overestimated
given that dose adjustments were driven by a treatment
algorithm that required a dose change for even minor
excursions above a threshold, an action not likely to be
commonly taken in the clinic. Approximately 88% or more
of HF patients with CKD, diabetes, and mild hyperkalaemia
and 73% or more of those with moderate hyperkalaemia
maintained normokalaemia at each visit between Weeks 12
and 52.
Of note, this is the first analysis that reports the long-term
safety of patiromer in patients with HF. Patiromer was gener-
ally well tolerated, and its long-term safety and tolerability
profile was similar in patients with and without HF at base-
line. Eight (7.6%) patients with HF, of whom five had EF
≤40%, discontinued patiromer because of AEs, with the most
common reason being worsening of CKD (three patients;
2.9%); however, none of the three cases in which worsening
of CKD occurred were deemed by the investigator to be re-
lated to patiromer. Overall, the majority of discontinuations
due to AEs were not patiromer related. The most common
gastrointestinal AE in patients with HF was diarrhoea
(4.8%), which was mild in all cases except for one patient
with moderate symptoms, and did not result in discontinua-
tion of patiromer. There was a low incidence of hypokalaemia
[serum potassium <3.5 mmol/L (3.8%)] and hypomagnesaemia
[serum Mg <0.49 mmol/L (1.9%)] over the 1-year study
duration; importantly, there were no episodes of sustained
ventricular arrhythmias or sudden cardiac death associated
with either hypomagnesaemia or hypokalaemia, including in
the patients with EF ≤40%. These results suggest that
hyperkalaemic patients with predominantly mild HF can take
patiromer chronically while maintaining their ACE-I and ARB
medication(s) without significantly increasing their risk of
cardiac arrhythmias due to shifts in serum electrolytes.
Serum calcium levels were measured during the study, and
mean levels remained within the normal range, with slight
(0.2 mmol/L) increases observed at Week 52 in patients with
HF. An 8.4 g dose of patiromer contains approximately 1.6 g
of calcium. As previously reported, at the maximal recom-
mended daily dose (25.2 g/day), patiromer administration in
healthy adults increased urine calcium by 1.82 mmol/day
(73 mg/day) and decreased urine phosphate by 0.67 mmol/
day (64 mg/day), suggesting that only a small fraction of
the calcium released from patiromer is available for absorp-
tion and that some of the released calcium may bind
phosphate.26
Of interest, mean systolic and diastolic BP were reduced
over 52 weeks in patients with and without HF. However, this
reduction is difficult to assess owing to a lack of a comparator
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group (placebo) but may be related to decreases in aldoste-
rone associated with a reduction in serum potassium, as seen
in OPAL-HK,27 and/or to an increase in binding of sodium to
patiromer and a consequent increase in the sodium excretion
in the faeces.26,28
Currently, patients with HF who develop hyperkalaemia
are advised to reduce their RAASi dose if their serum potas-
sium is >5.5 mmol/L and to discontinue RAASi therapy if
their serum potassium is ≥6.0 mmol/L.2 While this strategy
may avoid the consequences of hyperkalaemia such as an in-
crease in ventricular arrhythmias and sudden cardiac death, it
exposes patients to the long-term risks of progressive HF and
death, which prior studies have indicated are reduced by
chronic, continuous use of RAASi therapies.1–5,29 An analysis
of a large health records database for patients with ≥2 serum
potassium readings and ≥1 RAASi prescription showed that
nearly two-thirds of patients who had HF with or without
CKD were on lower than their target doses of RAASi and that
15% to 16% had discontinued RAASi therapy altogether.29
RAASi doses were reduced following 16% to 21% of all
hyperkalaemia events and discontinued following 22% to
27% of hyperkalaemia events in patients with cardiorenal
co-morbidities, suggesting that hyperkalaemia was an impor-
tant reason for RAASi dose reduction or discontinuation.30 A
recent follow-up analysis further showed that patients with
HF on maximum-recommended-dose RAASi had significantly
lower rates of adverse outcomes or death compared with
those on submaximum-dose RAASi.31 In HF patients
≥65 years, annualized total all-cause medical and pharmacy
costs were also significantly lower in the group on
maximum-recommended-dose RAASi compared with those
on submaximum-dose RAASi. Moreover, hyperkalaemia was
a strong predictor of annualized total all-cause medical and
pharmacy costs; and in patients with HF, it was associated
with a 50% increase in costs for patients <65 years and a
29% increase for those ≥65 years.31 Thus, a reduction to less
than the RAASi target dose or its discontinuation in a patient
with HF appears to increase the risk of serious adverse out-
comes, including death, as well as total costs.30,31
An alternative to reducing RAASi medications in patients
with HF complicated by hyperkalaemia would be to add a
potassium-binding polymer such as sodium polystyrene sulfo-
nate (SPS).32 However, this drug is poorly tolerated over the
long term and has been associated with the occurrence of
bowel necrosis.33,34 Furthermore, SPS exchanges sodium for
potassium and may increase total body sodium content;35
therefore, it must be used with caution in patients with
chronic HF, especially those with right HF who are at risk
for volume overload. An increase in sodium absorption in a
patient with volume overload (such as those with chronic
HF and/or CKD) could further exacerbate the symptoms and
consequences of volume overload with both short- and
long-term adverse consequences, including hospitalization
for HF and death. Patiromer, in contrast, exchanges calcium
for potassium, and its use in the prevention or treatment of
hyperkalaemia in patients with HF and/or CKD has not been
associated with any evidence of increased oedema or other
clinical evidence of volume overload.18,20,21,25
The availability of a well-tolerated and effective serum-
potassium-lowering agent, such as patiromer, that ex-
changes calcium rather than sodium for potassium may
have important implications for the management of pa-
tients with HF. Such an agent may enable more patients
with HF and a clinical indication for RAASi therapy to initi-
ate and maintain clinical-trial-proven doses of RAASi over
the long term. However, it will be important to educate pa-
tients with HF who are on RAASi and initiate a potassium
binder that they should not discontinue the latter without
consulting their physician. As shown in the current analysis,
discontinuing patiromer without concomitant modification
(dose reduction or discontinuation) of RAASi may lead to
a recurrence of hyperkalaemia and its clinical consequences.
Limitations
The study, although randomized, was not blinded. However, it
would be difficult to adequately blind a long-term study such
as this one because patients are likely to have their serum
potassium measured multiple times over the course of a year,
which may reveal their assignment to the study drug. Second,
the patients were identified as having HF based on physician
diagnosis and quantitative assessment of HF severity (e.g.
pro-BNP) was not available. Moreover the majority of HF pa-
tients had EF >40% and approximately one-quarter had
NYHA Class I symptoms. The mild nature of the HF in the
present analysis is consistent with the low use of MRA in this
subgroup (~5%). Therefore, further data will be required to
evaluate patiromer for the treatment of hyperkalaemia in
larger numbers of HF patients, including those with more se-
vere signs and symptoms of HF and an indication to receive
an MRA. Finally, by protocol, changes in RAASi medications
were allowed only for the management of BP, and so infer-
ences related to changes in RAASi use or doses in the context
of the treatment of hyperkalaemia in routine clinical practice
cannot be made. It should, however, be pointed out that 89
(85%) patients with HF enrolled in the present study were
able to maintain their RAASi for a period of up to 1 year with-
out the need to discontinue them owing to safety concerns
(Table S1).
Conclusions
The long-term administration of patiromer to hyperkalaemic
patients with a clinical diagnosis of HF appears to be effective
and well tolerated, consistent with the findings in patients
without a history of HF at baseline. The availability of an
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effective potassium-lowering agent such as patiromer, which
exchanges potassium for calcium rather than sodium, may in-
crease the number of HF patients who can maintain their
ACE-I or ARB at target doses over the long term. Further stud-
ies will be required to determine if patiromer, when used to
treat hyperkalaemia, allows maintenance of optimal doses
of MRAs in those indicated to receive them, especially
patients with EF ≤40%, as well as to determine if this strategy
improves clinical outcomes in HF patients in comparison with
the current approach of dose reduction or discontinuation of
RAASi in patients who develop hyperkalaemia.
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